JOINTECH Raises ￥100M in Series C Funding Round

(VCBeat) May. 20, 2021 -- Recently, JOINTECH Ltd. ("JOINTECH"), a technology company focusing on R&D and production of robot-assisted systems of orthopedic surgery, completed a Series C financing of hundreds of millions, led by LYFE Capital, with participation from SB China Capital, and the existing investors including GL Ventures and Fosun Pharma. JOINTECH has raised nearly 400 million yuan in one year. Haoyue Capital continued to serve as the exclusive financial advisor for this round. The funding will be used to advance the clinical trials of the surgical robot for knee replacement and the development and clinical application of other surgical robots and new products.

Established in 2018, JOINTECH has quickly become a leading platform enterprise of surgical robots for hard tissues in China with the team's rich experience, excellent combination of medical and industrial skills and strong executive ability. At present, JOINTECH's surgical robot for hip replacement has completed clinical enrollment and follow-up. It is also the first "surgical robot for total hip replacement" in China that has entered the special review procedure of innovative medical instruments by NMPA.It is expected to become the first domestic joint replacement surgical robot approved. In addition, the company has a number of surgical robots and other new products in the R&D or the stage of submission.

With the deep accumulation of the team in the field of surgical robots, JOINTECH has expanded its product pipeline to the field of knee replacement surgical robots and others. Among them, the robot for knee joint will start formal clinical trials soon, and hold the company's technical advantages in the field of the hip joint.

Founded in 2015, LYFE Capital is a dedicated healthcare fund with US$1.27 billion in assets under management. Its investment focus spans biopharmaceuticals, medical devices, and diagnostics.

Established in 2000, SBCVC is a leading venture capital and private equity firm that manages both USD and RMB funds. Its investment focuses on high-tech, high-growth companies in TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors; and we invest across all stages of companies.